Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing

被引:5
作者
Stefic, Karl [1 ,2 ]
Salmona, Maud [3 ,4 ]
Capitao, Marisa [3 ,4 ]
Splittgerber, Marion [3 ,4 ]
Maakaroun-Vermesse, Zoha [5 ]
Nere, Marie-Laure [3 ,4 ]
Bernard, Louis [5 ]
Chaix, Marie-Laure [3 ,4 ]
Barin, Francis [1 ,2 ]
Delaugerre, Constance [3 ,4 ]
机构
[1] Univ Tours, Inserm U966, Tours, France
[2] CHU Bretonneau, VIH, Lab Bacteriol Virol & Ctr Natl Reference, Tours, France
[3] Univ Paris Diderot, Inserm U941, Paris, France
[4] Hop St Louis, APHP, Lab Virol, Paris, France
[5] CHU Bretonneau, Med Interne & Malad Infectieuses, Tours, France
关键词
HIV-1; RESISTANCE; RALTEGRAVIR; EMERGENCE; FAILURE; IMPACT;
D O I
10.1093/jac/dkw507
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Ultra-deep sequencing (UDS) allows detection of minority resistant variants (MRVs) with a threshold of 1% and could be useful to identify variants harbouring single ormultiple drug-resistancemutations (DRMs). Objectives: We analysed the integrase gene region longitudinally using UDS in an HIV-1-infected child rapidly failing a raltegravir-based regimen. Methods: Longitudinal plasma samples at baseline and weeks 4, 8, 13, 17 and 39 were obtained, as well as the mother's baseline plasma sample. Sanger sequencing and UDS were performed on the integrase gene using Roche 454 GS-Junior. A bioinformatic workflow was developed to identify the major DRMs, accessory mutations and the linkage between mutations. Results: In Sanger sequencing and UDS, no MRV in the integrase gene was detected at baseline in either the mother or the child. Themajor DRM N155H conferring resistance to raltegravir and elvitegravirwas detected in4% of the sequences by week 4 using UDS, whereas it was not detected by Sanger sequencing. The double mutant E92Q + N155H, conferring resistance to the entire integrase inhibitor class, including dolutegravir, emerged at week 8 (16%) and became rapidly dominant (57% by week 13). At the last timepoint under raltegravir (week 17), Y143R emerged, leading to different resistancemutation patterns: singlemutants N155H (47%) and Y143R (24%) and doublemutants E92Q+N155H (13%), Y143R+N155H ( 2%) and E92Q+Y143R (2%). The polymorphic substitution M50Iwas preferentially selected on resistant variants, especially on E92Q+N155H variants. Conclusions: This case study illustrates the usefulness of UDS in detecting early MRVs and determining the dynamics of selected HIV-1 variants in longitudinal analysis.
引用
收藏
页码:850 / 854
页数:5
相关论文
共 31 条
[21]   Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing [J].
Clutter, Dana S. ;
Zhou, Shuntai ;
Varghese, Vici ;
Rhee, Soo-Yon ;
Pinsky, Benjamin A. ;
Fessel, W. Jeffrey ;
Klein, Daniel B. ;
Spielvogel, Ean ;
Holmes, Susan P. ;
Hurley, Leo B. ;
Silverberg, Michael J. ;
Swanstrom, Ronald ;
Shafer, Robert W. .
JOURNAL OF INFECTIOUS DISEASES, 2017, 216 (03) :387-391
[22]   Prevalence of Primary Resistance Mutations to Integrase Inhibitors in Treatment-Naive and -Experienced Patients Infected With B and Non-B HIV-1 Variants [J].
Gutierrez, Carolina ;
Hernandez-Novoa, Beatriz ;
Jesus Perez-Elias, Maria ;
Maria Moreno, Ana ;
Holguin, Africa ;
Dronda, Fernando ;
Luis Casado, Jose ;
Moreno, Santiago .
HIV CLINICAL TRIALS, 2013, 14 (01) :10-16
[23]   'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing [J].
Alteri, Claudia ;
Santoro, Maria Mercedes ;
Abbate, Isabella ;
Rozera, Gabriella ;
Bruselles, Alessandro ;
Bartolini, Barbara ;
Gori, Caterina ;
Forbici, Federica ;
Orchi, Nicoletta ;
Tozzi, Valerio ;
Palamara, Guido ;
Antinori, Andrea ;
Narciso, Pasquale ;
Girardi, Enrico ;
Svicher, Valentina ;
Ceccherini-Silberstein, Francesca ;
Capobianchi, Maria Rosaria ;
Perno, Carlo Federico .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (11) :2615-2623
[24]   Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data [J].
Vingerhoets, J. ;
Calvez, V. ;
Flandre, P. ;
Marcelin, A-G ;
Ceccherini-Silberstein, F. ;
Perno, C-F ;
Santoro, M. Mercedes ;
Bateson, R. ;
Nelson, M. ;
Cozzi-Lepri, A. ;
Grarup, J. ;
Lundgren, J. ;
Incardona, F. ;
Kaiser, R. ;
Sonnerborg, A. ;
Clotet, B. ;
Paredes, R. ;
Guenthard, H. F. ;
Ledergerber, B. ;
Hoogstoel, A. ;
Nijs, S. ;
Tambuyzer, L. ;
Lavreys, L. ;
Opsomer, M. .
HIV MEDICINE, 2015, 16 (05) :297-306
[25]   Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay [J].
Lee, Sook-Kyung ;
Zhou, Shuntai ;
Baldoni, Pedro L. ;
Spielvogel, Ean ;
Archin, Nancie M. ;
Hudgens, Michael G. ;
Margolis, David M. ;
Swanstrom, Ronald .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (02) :221-228
[26]   Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission [J].
Hauser, Andrea ;
Kuecherer, Claudia ;
Kunz, Andrea ;
Dabrowski, Piotr Wojtek ;
Radonic, Aleksandar ;
Nitsche, Andreas ;
Theuring, Stefanie ;
Bannert, Norbert ;
Sewangi, Julius ;
Mbezi, Paulina ;
Dugange, Festo ;
Harms, Gundel ;
Meixenberger, Karolin .
PLOS ONE, 2015, 10 (10)
[27]   Low-Level Ionizing Radiation Induces Selective Killing of HIV-1-Infected Cells with Reversal of Cytokine Induction Using mTOR Inhibitors [J].
Pinto, Daniel O. ;
DeMarino, Catherine ;
Vo, Thy T. ;
Cowen, Maria ;
Kim, Yuriy ;
Pleet, Michelle L. ;
Barclay, Robert A. ;
Noren Hooten, Nicole ;
Evans, Michele K. ;
Heredia, Alonso ;
Batrakova, Elena, V ;
Iordanskiy, Sergey ;
Kashanchi, Fatah .
VIRUSES-BASEL, 2020, 12 (08)
[28]   High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO [J].
Bouassa, Ralph-Sydney Mboumba ;
Mossoro-Kpinde, Christian Diamant ;
Gody, Jean-Chrysostome ;
Veyer, David ;
Pere, Helene ;
Matta, Mathieu ;
Robin, Leman ;
Gresenguet, Gerard ;
Charpentier, Charlotte ;
Belec, Laurent .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (07) :2030-2038
[29]   In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors [J].
Koh, Yasuhiro ;
Amano, Masayuki ;
Towata, Tomomi ;
Danish, Matthew ;
Leshchenko-Yashchuk, Sofiya ;
Das, Debananda ;
Nakayama, Maki ;
Tojo, Yasushi ;
Ghosh, Arun K. ;
Mitsuya, Hiroaki .
JOURNAL OF VIROLOGY, 2010, 84 (22) :11961-11969
[30]   Study of antibody repertoires to the CD4 binding site of gp120 of a Chinese HIV-1-infected elite neutralizer, using 454 sequencing and single-cell sorting [J].
Li, Dan ;
Wang, Zheng ;
Ren, Li ;
Zhang, Jing ;
Feng, Guangda ;
Hong, Kunxue ;
Hao, Yanling ;
Qi, Zhi ;
Liang, Hua ;
Shao, Yiming .
ARCHIVES OF VIROLOGY, 2016, 161 (04) :789-799